[Click eStock] "Vistos, uniquely undervalued AI medical... Similar to Google project"

ResearchAlum predicted on the 26th that Vistos would benefit as the government steps up support to address the low birthrate issue.

Founded in 2001, Vistos is a manufacturer of biomedical signal diagnostic medical devices. It mainly produces medical devices related to fetuses and newborns. More than 90% of its sales are achieved through exports.

Researcher Choi Seong-hwan of ResearchAlum explained, "We hold various core technology patents related to biomedical signal measurement and analysis," adding, "There are 23 products certified with the European CE mark and 13 products approved by the U.S. Food and Drug Administration (FDA)."

He continued, "The home-use artificial intelligence (AI) fetal heart rate monitor is currently undergoing medical device certification procedures," and "The hospital-use multifunctional smart incubator has entered prototype production, with commercialization planned by the end of this year."

He emphasized, "AI has the potential to improve the accuracy, efficiency, and speed of disease and condition diagnosis," and "Vistos, as a medical device manufacturer in the biomedical signal diagnostic field, is preparing to launch a variety of AI-equipped product lines."

Researcher Choi forecasted, "Vistos’ AI fetal heart rate monitor ‘BT-210’ is a model similar to the project being developed by Google, capable of analyzing fetal ultrasound heartbeats to assess fetal health status." He added, "Next year, the company is expected to grow rapidly by selling multifunctional smart incubators and home-use fetal heart rate monitors equipped with AI technology."

Last year, Google launched a fetal health management project using AI technology in collaboration with Northwestern University Medical School. They are developing an algorithm that can interpret ultrasound data taken by locally trained health workers or pregnant women at home. It is expected to be used for diagnosis and prevention by easily assessing the health status of mothers and fetuses, similar to measuring body temperature.

He stated, "Recently, companies specializing in AI medical diagnosis such as Lunit and Vuno have emerged prominently, and Vistos has also secured a very attractive business portfolio." He presented a positive stock price outlook with a target price of 3,500 KRW.

Last year, sales reached 24 billion KRW, a 16.8% increase compared to the previous year. Sales of breast pumps in the U.S. market surged, increasing sales in the home-use product sector from 1.8 billion KRW in 2021 to 5.2 billion KRW last year, a 185.7% increase. This year, sales are estimated to reach 30 billion KRW and operating profit 2.5 billion KRW, representing increases of 25.2% and 171.9% respectively compared to last year.